Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers
Journal of the American College of Cardiology2022Vol. 81(1), pp. 1–12
Citations Over TimeTop 1% of 2022 papers
Luke J. Laffin, Dennis Bruemmer, M. Gómez García, Danielle M. Brennan, Ellen McErlean, Douglas S. Jacoby, Erin D. Michos, Paul M. Ridker, Tracy Y. Wang, Karol E. Watson, Howard G. Hutchinson, Steven E. Nissen
Abstract
Among individuals with increased 10-year risk for ASCVD, rosuvastatin 5 mg daily lowered LDL-C significantly more than placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice. (Supplements, Placebo, or Rosuvastatin Study [SPORT]; NCT04846231).
Related Papers
- → Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults(2021)27 cited
- → Rosuvastatin for lowering lipids(2014)70 cited
- → An Economic Evaluation of Rosuvastatin Treatment in Systolic Heart Failure: Evidence from the CORONA Trial(2009)20 cited
- → Rosuvastatin: winner in the statin wars, patients' health notwithstanding(2015)13 cited
- → Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention(2013)5 cited